Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 7/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641629 | 0.88 | BRD4 (0.59) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL1640326 | 0.86 | HSP90AA1 (0.58) | HTTBRD4BRD2BRD3BRDT | |
| SCHEMBL1640573 | 0.85 | BRD4 (0.65) | HTTBRD4BRD2BRD3BRDT | |
| SCHEMBL1641827 | 0.81 | BRD4 (0.57) | BRD4BRD2BRD3BRDT | |
| SCHEMBL1642053 | 0.81 | MAPT (0.59) | HTTBRD4BRD2BRD3BRDT | |
| SCHEMBL1640352 | 0.80 | LMNA (0.55) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL1642209 | 0.80 | EGLN1 (0.53) | EGLN1HTTALDH1A1SMN1; SMN2EGLN3 | |
| SCHEMBL1641959 | 0.80 | KDM4E (0.48) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL1641375 | 0.79 | HSP90AA1 (0.53) | HTTALDH1A1SMN1; SMN2CNR2EGLN3 | |
| SCHEMBL1641854 | 0.79 | KDM4E (0.53) | BRD4BRD2BRD3BRDTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2306828-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxosmithkline LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885HTT 2608/4885BRD4 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.